Oral Solid Dosage CDMO Market (2026 - 2033)

Oral Solid Dosage CDMO Market Summary

The global oral solid dosage CDMO market size was estimated at USD 46.4 billion in 2025 and is projected to grow from USD 49.3 billion in 2026 to USD 77.1 billion by 2033, growing at a CAGR of 6.6% from 2026 to 2033. The North America market held the largest share of 30.5% of the global market in 2025. The market growth is driven by a rising demand for cost-efficient drug development, increasing outsourcing by pharmaceutical and biotech companies, and growing consumption of tablets and capsules for chronic and lifestyle diseases, owing to ease of administration and precise dosage, which enhances the requirement for oral solid dosage CDMO services.

Other factors contributing to market growth include the expansion of generic drugs, patent expiries, and the need for flexible manufacturing capacity. Most companies rely on CDMOs to access advanced formulation capabilities, scale up production efficiently, and meet stringent regulatory and quality requirements. In addition, technological advancement and increased reliance on CDMOs for end-to-end OSD development and manufacturing services are expected to drive the market.

The growing prevalence of chronic and infectious diseases is a significant factor driving the demand for novel therapies. In addition, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel therapies. Another factor contributing to market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Moreover, several solid dosage forms are currently available on the market due to ongoing advancements in drug delivery technology, rising investments by contract development and manufacturing organizations (CDMOs) to expand OSD development, and increasing demand for novel therapies, all of which further contribute to market growth.

Furthermore, technological advancements in the development and bulk manufacturing of OSD forms are among the key factors supporting the fast-track commercialization of these products. In addition, the pharmaceutical/biopharmaceutical & nutraceutical industries are focusing on developing OSD forms owing to their convenient consumption, ease of handling, and patient adherence. Moreover, advancements in technology and materials of OSD products are expected to boost the demand for these formulations. The requirement for patient-centric dosage forms has increased in the past few years to improve medication adherence. Thus, the integration of advanced technologies in facilities enables enhanced manufacturing and development capabilities with reduced costs and time.

3D printing in OSD manufacturing enables precise control over drug release and the creation of customized dosage forms, thereby addressing patient-specific needs. This technology supports complex designs, enhancing flexibility in drug development. Controlled-release advancements improve delivery, fostering sustained efficacy and compliance. Digital technologies and data analytics further streamline process monitoring and quality control, making CDMO solutions more transparent and data-driven, further supporting the market. Such factors are expected to drive the market.

Market Dynamics

The oral solid dosage (OSD) CDMO market is witnessing strong growth, supported by rising pharmaceutical outsourcing, increasing generic drug development, and growing demand for cost-efficient manufacturing solutions. Currently, most of the pharmaceutical, specialty pharma, and virtual companies are increasingly partnering with CDMOs to reduce capital expenditure, access GMP-compliant production capacity, and accelerate product development timelines. Besides, the demand is particularly strong among small and mid-sized companies that lack in-house formulation, scale-up, clinical batch, and commercial manufacturing capabilities.

In addition, market expansion is further supported by growing outsourcing of formulation development, tablet and capsule manufacturing, packaging and labelling, regulatory documentation, and technology transfer services. CDMOs are also gaining traction as sponsors seek flexible manufacturing models and integrated development-to-commercial supply support across tablets, capsules, powders, granules, and differentiated oral solid formats. Moreover, the growth opportunities are emerging through regional manufacturing expansion, long-term supply partnerships, lifecycle management support, and end-to-end service models, strengthening CDMOs’ role as strategic outsourcing partners.

Market Concentration & Characteristics

The market growth stage is medium, and the pace of the market growth is accelerating, characterized by an increasing number of M&A activities, the impact of regulations, service expansions, and regional expansions. The oral solid dosage CDMO industry is characterized by a high degree of innovation driven by continuous advancements in manufacturing technology, such as 3D printing, process analytical technology (PAT, and machine learning. Moreover, market participants are focusing on developing novel solutions and methodologies to improve the efficiency and effectiveness of product development processes, including personalized medicine, advanced drug delivery systems, and novel solutions.

High impact of regulations on the oral solid dosage CDMO industry. The OSD CDMO market is highly influenced by regulatory requirements enforced by several regulatory authorities, such as the U.S. FDA and the EMA, among others. Stringent regulations regarding development and manufacturing standards, quality control, and documentation significantly impact overall market dynamics.

The medium level of M&A in the oral solid dosage CDMO industry is driven by the growing need for companies to expand their capabilities, geographic presence, and service offerings. For instance, in April 2023, NextPharma acquired a chewable tablets manufacturing facility from Takeda in Norway. This acquisition expanded the company’s operational capabilities in the market.

Several industry participants are undertaking collaborations and partnerships with pharmaceutical companies, research institutions, and technology providers to accelerate service expansions. For instance, in January 2023, Ethicann and Catalent collaborated for the development of Ethicann’s clinical drug pipeline by using Catalent’s ODT technology. Further, Investments in innovative technologies such as continuous manufacturing, automation, and data analytics enable CDMOs to offer better efficiency and cost-effective solutions to their clientele, thereby driving overall market growth.

The oral solid dosage CDMO industry is characterized by a medium impact of regional expansion driven by factors such as chronic disease burden, increasing healthcare expenditures, and high demand for OSD. Several service providers are broadening their presence in emerging markets such as the Asia Pacific and Latin America by establishing manufacturing and R&D facilities and strategic alliances with domestic players to gain market access and new revenue growth avenues.

Analyst Perspective

The oral solid dosage CDMO market is currently witnessing shifting trends from capacity-led outsourcing toward complexity-led partnerships. Recent demand is increasingly concentrated around controlled-release products, high-potency oral solids, ODTs, differentiated capsules, and patient-centric dosage formats, as sponsors seek formulation expertise beyond conventional tablet and capsule manufacturing. CDMOs with advanced containment, coating, granulation, and modified-release capabilities are gaining stronger pricing power and customer stickiness. In addition, continuous manufacturing, digital quality systems, serialization, and sustainable packaging are becoming key operating priorities, supporting efficiency, compliance, and supply chain resilience. Outsourcing demand is also being reinforced by patent expirations, generic competition, and the need for flexible clinical-to-commercial scale-up. Moreover, growing competitive advantage will depend on integrated development-to-manufacturing platforms, regulatory reliability, technology-enabled execution, and the ability to support complex OSD programs across global and regional supply networks.

Technological Advancements

The OSD CDMO market is experiencing significant technological advancements, enhancing drug development and manufacturing processes. Continuous manufacturing has emerged as a pivotal innovation, enabling uninterrupted production flows that improve efficiency, consistency, and cost-effectiveness. This approach reduces transfer steps and contamination risks by integrating multiple unit operations into a single process. In addition, 3D printing technologies, particularly 3D screen printing, are revolutionizing personalized medicine by allowing precise control over drug composition and dosage, thereby facilitating the production of tailored medications tailored to individual patient needs.

Advanced drug delivery systems, such as Self-Microemulsifying Drug Delivery Systems (SMEDDS), are improving the bioavailability of poorly soluble drugs, enhancing therapeutic efficacy. Furthermore, the integration of digital tools, such as predictive modeling and automation platforms, accelerates formulation development, thereby reducing time and resource requirements. These digital advancements enable rapid optimization of tablet formulations, ensuring critical quality attributes are met efficiently.

Pricing Model Analysis

In the oral solid dosage CDMO industry, pricing models play a pivotal role in aligning client expectations with service delivery, risk-sharing, and long-term collaboration. Four key pricing structures commonly employed are milestone-based, value-based, fixed-fee, and subscription/retainer models. This pricing model offers strategic benefits that vary according to project complexity, client size, and engagement duration.

Milestone-based pricing is widely used for complex development or scale-up projects. Payments are linked to the achievement of defined technical or regulatory milestones, helping to mitigate risk for both CDMOs and sponsors. This model fosters accountability but can lead to negotiation complexity and extended timelines if milestone definitions are ambiguous. Value-based pricing is gaining traction as CDMOs aim to align compensation with the therapeutic or commercial value they help generate. This model ties pricing to improved bioavailability, faster time-to-market, or higher yields. It rewards innovation and performance but requires sophisticated metrics and trust between partners.

The fixed-fee model offers predictability, particularly for standardized tasks such as tablet compression or batch manufacturing. It simplifies sponsor budgeting and reduces administrative overhead, though it can disincentivize flexibility and innovation in long-term projects. The subscription or retainer model is emerging for clients seeking ongoing development or manufacturing support. This approach involves recurring monthly or quarterly fees, enabling steady resource allocation and long-term partnership. While beneficial for capacity planning, it may be less suitable for clients with sporadic or project-based needs.

Product Insights

Based on product type, the tablets segment led the market with the largest revenue share of 32.1% in 2025 and is expected to grow at the fastest CAGR over the forecast period. The segment growth is driven by its broad applicability, diverse formulations, patient preference, and global acceptance. The growing integration of technological advancements, such as continuous manufacturing and 3D printing, among facilities is expected to enhance segment growth by improving the efficiency of overall manufacturing processes. Moreover, strategic initiatives by key players, such as capacity expansion, partnerships, and collaborations, are projected to fuel market growth in the near future. For instance, in April 2023, Thermo Fisher Scientific expanded the capabilities of its France site to incorporate early development activities for oral solid dose therapies, including tablets, capsules, and granules. This enabled the company to seamlessly cater to customers’ workflow, from the initial stages of drug development to commercial manufacturing.

On the other hand, the capsules segment is expected to grow at the fastest CAGR over the forecast period. The segment growth is driven by its advantages, such as easy swallowing, faster disintegration, taste masking, and improved absorption. Increased demand for encapsulated formulations, fueled by the growth of the global pharmaceutical sector, is driving the need for specialized CDMOs that efficiently deliver high-quality, customized hard gelatin capsules.

Mechanism Insights

Based on mechanism, the controlled release segment led the market with the largest revenue share of 53.0% in 2025. The segment growth is driven rising demand for formulations that improve dosing convenience, therapeutic consistency, and patient adherence. The segment covers outsourced development and manufacturing of modified-release tablets, capsules, pellets, and multiparticulate systems designed to release active ingredients over the forecast period. Besides, the growth is supported by increasing use of controlled-release formats in chronic disease treatment, lifecycle management of established drugs, and differentiated generic development. CDMOs with formulation expertise and scalable coating technologies benefit the market.

On the other hand, the immediate release segment is expected to grow at the fastest CAGR over the forecast period, driven by increasing demand for rapid drug absorption and the onset of action among patients, fueling segment growth. In addition, continuous advancements in formulation technologies and manufacturing processes offer CDMOs the opportunity to develop immediate-release drugs with enhanced bioavailability and therapeutic efficacy. Besides, the expanding pharmaceutical outsourcing trend and the outsourcing of immediate-release drug manufacturing by pharmaceutical companies to CDMOs are driving the growth of this market segment. Such factors are expected to drive the market growth over the estimated time period.

Drug Potency Insights

Based on drug potency, the low potent drugs segment led the market with the largest revenue share of 48.7% in 2025. The segment growth is driven by high-volume outsourcing demand for conventional tablets, capsules, and granules. These drugs are widely used across chronic disease therapies, including cardiovascular, metabolic, gastrointestinal, and pain management indications, supporting steady commercial-scale manufacturing requirements. Besides, the segment benefits from comparatively simpler containment needs, lower operational complexity, faster technology transfer, and broader CDMO capacity availability. In addition, growing demand for cost-efficient generic and branded oral solid formulations further supporting the market growth. 

On the other hand, the high potent drugs segment is expected to grow at the significant CAGR over the forecast period. The segment is driven by increasing outsourcing demand for oncology, hormonal, immunosuppressant, and targeted therapies. Besides, the growth is due to expanding pipelines of potent small molecules, rising demand for niche therapies, and sponsors’ preference for CDMOs with dedicated HPAPI handling expertise and GMP-compliant infrastructure. Such factors are expected to drive the market growth

Service Insights

Based on service, the contract development segment led the market with the largest revenue share of 58.9% in 2025 and is expected to grow at the fastest CAGR over the forecast period. Segment growth is driven by increasing requirements for early-stage formulation, analytical method development, stability testing, and bioequivalence work, which necessitate highly specialized scientific expertise and advanced laboratory infrastructure; thus, many pharmaceutical companies prefer to outsource rather than build in-house capabilities. Regulatory requirements from agencies like the FDA and EMA (e.g., ICH M13 bioequivalence guidance for solid oral forms) further push drug sponsors to rely on experienced development partners to ensure compliance.

The contract manufacturing segment is expected to witness the fastest growth, driven by a growing pharmaceutical pipeline, expanding large-volume commercial production of tablets and capsules as more drugs progress beyond development. Besides, companies are increasingly outsourcing manufacturing to avoid high capital costs, gain supply-chain flexibility, and access specialized high-potency or continuous manufacturing technologies. Such factors are expected to drive the market growth.

End Use Insights

Based on end use, the medium & small size companies segment led the market with the largest revenue share of 72.5% in 2025. The segment growth is attributed to the increasing number of small & medium-sized companies outsourcing their production work to CDMOs and CMOs. Medium and small-sized pharmaceutical companies have limited resources and capabilities in formulation development, process optimization, and manufacturing of oral solid dosage forms. Outsourcing allows them to access specialized expertise, advanced technologies, and state-of-the-art facilities offered by CDMOs without significant upfront investment. Increasing strategic initiatives by business players is another key factor contributing to segment growth. In August 2021, Recro Pharma, Inc., also known as Societal CDMO, acquired IRISYS, a U.S.-based CDMO involved in oral solid dosage contract development and manufacturing. This acquisition broadened the company’s business capabilities to cater to a diverse client base and financial position.

The large-sized companies segment is expected to witness the significant growth, driven by an increasing number of large-sized companies outsourcing their production work to CDMOs and CMOs. Large pharmaceutical companies have numerous resources and capabilities in formulation development, process optimization, and the manufacturing of oral solid dosage forms. Outsourcing allows them to access specialized expertise, advanced technologies, and state-of-the-art facilities offered by CDMOs without significant upfront investment. By partnering with CDMOs, these companies can leverage variable cost structures, optimize resource utilization, & reduce overall operational expenses, enabling them to allocate resources more efficiently and focus on core business activities.

Regional Insights

North America dominated the oral solid dosage CDMO market with the largest revenue share of 30.5% in 2025. North America oral solid dosage CDMO market growth can be attributed to growing investments in R&D of new drugs by pharmaceutical companies. The growth of the pharmaceutical industry in the U.S. and Canada is a key factor contributing to market growth. In addition, the substantial presence of key industry players and continuous clinical trials is anticipated to drive market growth. Moreover, within North America, the U.S. market held the largest share in the region. Increasing R&D investments, growing drug development costs, expensive raw ingredients, and a rising need for oral solid dosage products are driving numerous pharmaceutical entities in the U.S. to outsource key aspects of the drug development process. Such factors are expected to drive the market.

U.S. Oral Solid Dosage CDMO Market Trends

The oral solid dosage CDMO market in the U.S. held the largest share in the North America region in 2025. The oral solid dosage CDMO market in the U.S. is driven by rising demand for tablets and capsules, increasing prevalence of chronic diseases, and greater outsourcing by pharmaceutical companies to reduce operational costs. Besides, most of the CDMOs are benefiting from expanding generic drug production, the need for specialized formulation capabilities, and stricter quality standards that encourage reliance on expert partners, which is expected to drive the market growth. In addition, the growing need for tablet manufacturing, increasing focus on cost efficiency, and scalability are further contributing to market growth. Moreover, growing advancements in controlled-release technologies, continuous manufacturing, and flexible production capacity further support market expansion as drug developers seek reliable, compliant, and efficient OSD manufacturing solutions. Such factors are expected to drive the market.

Europe Oral Solid Dosage CDMO Market Trends

The oral solid dosage CDMO market in Europe is anticipated to experience significant growth due to the presence of key pharmaceutical companies. The country is driven by a robust pharmaceutical sector, comprising numerous companies engaged in drug discovery, development, and manufacturing. These CDMOs are investing in upgrading existing capabilities to meet the rising demand, divesting their business segments to increase focus on expanding their market reach within the region. Such factors are expected to drive the market.

Germany oral solid dosage CDMO market held the largest share in 2024. This market is driven by robust Technological advancements in pharmaceutical drug product development by CDMOs in the region, which is a significant factor responsible for market growth. The OSD CDMO industry significantly benefits from robust R&D initiatives, advanced early innovation medicine platforms, and numerous clinical trials targeting various disease challenges, which is expected to drive the market growth.

The oral solid dosage CDMO market in the UK is anticipated to grow over the forecast period. This growth is primarily due to the presence of numerous multinational CDMOs in the country. Moreover, the pharmaceutical manufacturers in the UK are focusing on the innovation of various high-value tablet forms in bulk, which has created a demand for oral solid dosage CDMOs in the country. Such factors are expected to drive the market growth.

Asia Pacific Oral Solid Dosage CDMO Market Trends

The oral solid dosage CDMO market in the Asia Pacific held the largest market share of 36.9% in 2025. This growth can be attributed to various factors, including India and China being major OSD CDMO players that offer competitively low prices compared to other regions. Generic drug manufacturing, bolstered by patent expirations, is the second-largest revenue source in the Asia Pacific. Growth in countries such as India and China has been driven by improved social insurance, better economic conditions, and increased manufacturing capacities, distinguishing the region from others in both scale and expansion. China held the largest market share in the Asia Pacific in 2024. Ongoing pharmaceutical advancements and increasing demand for quality are driving market growth. Such factors are expected to drive the market growth.

Japan oral solid dosage CDMO market is the Asia Pacific region's second-largest. The country is strengthening its position in the market by Rapid advancements in drug delivery technology, such as targeted drug delivery and sustained-release dosage forms. Such factors are expected to drive the market.

The oral solid dosage CDMO market in India is expected to experience significant growth at a significant CAGR during the forecast period. The country has become one of the most preferred sites due to its low costs, the availability of industry experts, the presence of WHO-cGMP-compliant facilities, and its high manufacturing capabilities for generic drugs and cost-effective oral solid dosage packaging solutions. As per June 2023 data by PIB, the country ranks third globally in terms. Such factors are expected to drive the market.

Key Oral Solid Dosage CDMO Company Insights

Market players are undertaking various strategic initiatives, such as the launch of new product innovations, collaborations, partnerships, and mergers & acquisitions, to strengthen their service offering and provide a competitive advantage. For instance, in January 2024, Alcami Corporation acquired Pacific Pharmaceutical Services, Inc., a cGMP pharma storage and services provider. Such an acquisition offered numerous growth opportunities to the company in a significant market.

• Lonza is a leading global CDMO with over 30 sites in Europe, North America, and Asia. It provides end-to-end services for oral solid dosage drugs, including tablets, capsules, and powders. Moreover, its services include the development of drug formulation, clinical supply, commercial manufacturing, and packaging.

Key Oral Solid Dosage CDMO Companies

The following key companies have been profiled for this study on the oral solid dosage CDMO market.

• Lonza

• Thermo Fisher Scientific Inc.

• Cambrex Corporation

• Catalent Inc.

• Siegrfried Holding AG

• Recipharm AB

• CordenPharma International

• Boehringer Ingelheim

• Piramal Pharma Solutions

• Aenova Group

• Almac Group

• Jubilant Pharmova Limited

• Delpharm

• AbbVie Contract Manufacturing

• Next Pharma AB

• Rubicon Research Pvt. Ltd.

• Quotient Sciences

• SPI Pharma

• DPT Laboratories Ltd.

• Alcami Corporation

Competitive Benchmarking

Recent Developments

• In February 2024, Novo Holdings announced the acquisition of Catalent Inc., a prominent CDMO in the healthcare industry. Through this acquisition, Novo Holdings will gain significant market growth opportunities, and Catalent will broaden its operational capabilities.

• In July 2023, Aenova Group partnered with Galvita to improve the formulation, production, and development of oral dosage forms. This partnership helped to broaden the company’s service offerings in the market.

Oral Solid Dosage CDMO Market Report Scope

Global Oral Solid Dosage Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral solid dosage CDMO market report based on product, mechanism, drug potency, service, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Tablets

    • Compressed Tablets

    • Orally Disintegrating Tablets (ODT)

    • Chewable Tablets

    • Bi-layer or Tri-layer Tablets

    • Sublingual or Buccal Tablets

    • Others

  • Capsules

    • Hard Gelatin Capsules

    • Soft Gelatin Capsules

  • Powders

  • Granules

  • Others

• Mechanism Outlook (Revenue, USD Million, 2021 - 2033)

  • Immediate Release

  • Delayed Release

  • Controlled Release

• Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)

  • High Potent Drugs

  • Moderate Potent Drugs

  • Low Potent Drugs

• Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Contract Development

  • Contract Manufacturing

  • Packaging and Labelling

  • Regulatory Affairs

  • Logistics & Storage

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Large Size Companies

  • Medium & Small Size Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Oman

    • Qatar

Research Methodology

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations